|Title:||Diltiazem formulations and methods of treatment|
|Abstract:||A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (Paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KC1 at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 80% of the total diltiazem is released after six hours of measurement and not less than 85% of the total diltiazem is released after 13 hours of measurement.|
|Inventor(s):||Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Gainesville, GA), Panoz; Donald E. (Tuckerstown, BM)|
|Assignee:||Elan Corporation, plc (Athlone, IE)|
|Filing Date:||May 19, 1993|
|Claims:||1. A method of controlling or preventing angina attacks or reducing the incidence of angina attacks in a subject suffering from angina pectoris, comprising administering to said subject on a once per 12 hour basis a dose effective to improve the blood supply and hence increase the oxygen supply in the myocardium of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption pellet formulation, said pellet comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmacetutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak myocardium oxygenating levels int eh blood 4 to 12 hours following administration. |
2. The method of claim 1 wherein the ratio of the diltiazem component and the organic acid is from about 19:1 to 1:1.
3. The method of claim 1 wherein a plurality of pellets are administered in capsule form.
4. The method of claim 1 wherein a plurality of pellets are administered in tablet form.